EDC-2

N/A

Report date: 2022/08/24 20:00:31

Base Information

Drug NameEDC-2

Drug Alias NameEDC-22

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)

Mechanisms of ActionATPase inhibitorsCytoadhesin receptors inhibitors

TargetsCytoadhesin receptorsATPase

Therapy Area/IndicationsHead and Neck Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesWisconsin Alumni Research Foundation

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesCentrose LLC

Active IndicationsN/A

Inactive IndicationsHead and Neck Neoplasms

Other Information

ATC CodeN/A